A new platform for predicting drug toxicity after liver metabolism
A recent study in ACS Pharmacology & Translational Science introduces a novel 96-well format-based liver–heart-on-a-chip platform designed for high-throughput testing of drug-induced cardiotoxicity following liver metabolism. This microphysiological system aims to better model the complex in vivo process where a drug is metabolized by the liver before its metabolites affect other organs, a critical factor in drug development and safety assessment. The platform facilitates parallel testing, potentially accelerating the identification of toxic compounds and improving the predictive accuracy of preclinical models for oncology and other therapeutic areas.
Why it might matter to you: For professionals in precision oncology, this technology addresses a key bottleneck in drug development: predicting off-target organ toxicity, including cardiotoxicity, which is a major concern for many kinase inhibitors and targeted therapies. The ability to test drug candidates in a more physiologically relevant, high-throughput system could streamline the pipeline for novel cancer therapeutics, reducing late-stage failures. It represents a significant step toward more reliable preclinical models that account for metabolic activation, directly impacting the development of safer, more effective targeted therapies.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
